AR074108A1 - Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina - Google Patents
Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarinaInfo
- Publication number
- AR074108A1 AR074108A1 ARP090104348A ARP090104348A AR074108A1 AR 074108 A1 AR074108 A1 AR 074108A1 AR P090104348 A ARP090104348 A AR P090104348A AR P090104348 A ARP090104348 A AR P090104348A AR 074108 A1 AR074108 A1 AR 074108A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- years old
- dabigatran
- history
- optionally
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 12
- 150000003839 salts Chemical class 0.000 title abstract 4
- 208000007536 Thrombosis Diseases 0.000 title abstract 3
- 229960003850 dabigatran Drugs 0.000 title abstract 3
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title abstract 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 title abstract 3
- 238000011443 conventional therapy Methods 0.000 title 1
- 208000006011 Stroke Diseases 0.000 abstract 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 4
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 3
- 229960000288 dabigatran etexilate Drugs 0.000 abstract 3
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 abstract 3
- 208000032843 Hemorrhage Diseases 0.000 abstract 2
- 208000034158 bleeding Diseases 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 229960003624 creatine Drugs 0.000 abstract 2
- 239000006046 creatine Substances 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 229960005080 warfarin Drugs 0.000 abstract 2
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un método para prevenir apoplejías en un paciente que sufre de fibrilacion auricular, donde el paciente no tiene factores de riesgo de episodios de sangrado graves, el método comprende administrar al paciente una dosis de >150 mg b.i.d. a 300mg b.i.d. de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo. Reivindicacion 7: El método de acuerdo con la reivindicacion 6, caracterizado porque el paciente no ha sido sometido a cirugía en un plazo de 90 días. Reivindicacion 14: El método de acuerdo con la reivindicacion 13, caracterizado porque el factor de riesgo de apoplejía, trombosis, o embolia se selecciona del grupo que consiste en; (a) tener una edad de al menos 75 anos; (b) tener un historial de apoplejías; (c) tener un historial de un ataque isquémico transitorio; (d) tener un historial de un episodio tromboembolico; (e) tener una disfuncion ventricular izquierda; (f) tener una edad de al menos 65 anos y tener presion sanguínea elevada; (g) tener una edad de al menos 65 anos y tener diabetes; (h) tener una edad de al menos 65 anos y tener una enfermedad arterial coronaria; y (i) tener una edad de al menos 65 anos y tener una enfermedad arterial periférica. Reivindicacion 16: El método de acuerdo con la reivindicacion 13, caracterizado porque el paciente tiene fibrilacion auricular. Reivindicacion 22: Un método para prevenir o tratar la trombosis en un paciente necesitado de dicho tratamiento, caracterizado porque el método que comprende administrar una dosis de >150 mg b.i.d. a 300mg b.i.d. de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo, donde para el paciente no es adecuada la terapia convencional con warfarina. Reivindicacion 24: El método de acuerdo con la reivindicacion 5, caracterizado porque en donde el paciente tiene una depuracion de creatina mayor que 30 mL/min. Reivindicacion 25: El método de acuerdo con la reivindicacion 5, caracterizado porque además comprende discontinuar la administracion de dabigatrán si el paciente tiene una depuracion de creatina de 30 mL/min., o menos. Reivindicacion 34: Un método para prevenir apoplejías en un paciente con fibrilacion auricular, caracterizado porque el método comprende administrar de >150 mg b.i.d a 300 mg b.i.d de etexilato de dabigatrán, opcionalmente en la forma de una sal aceptable para uso farmacéutico del mismo, al paciente y modificar la administracion segun sea necesario para mantener los niveles de dabigatrán en plasma en el paciente entre aproximadamente 20 ng/mL y aproximadamente 180 ng/mL, donde el paciente está en un riesgo reducido de un episodio de sangrado grave en comparacion con la terapia convencional con warfarina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11341308P | 2008-11-11 | 2008-11-11 | |
| US23756609P | 2009-08-27 | 2009-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074108A1 true AR074108A1 (es) | 2010-12-22 |
Family
ID=41463077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104348A AR074108A1 (es) | 2008-11-11 | 2009-11-10 | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110251160A1 (es) |
| EP (1) | EP2358367A1 (es) |
| JP (1) | JP2013510074A (es) |
| KR (1) | KR20110082563A (es) |
| CN (2) | CN103340860A (es) |
| AR (1) | AR074108A1 (es) |
| AU (1) | AU2009315731A1 (es) |
| BR (1) | BRPI0921353A2 (es) |
| CA (1) | CA2738885A1 (es) |
| CL (1) | CL2011000805A1 (es) |
| IL (1) | IL211854A0 (es) |
| MX (1) | MX2011004534A (es) |
| NZ (1) | NZ592613A (es) |
| RU (1) | RU2530645C2 (es) |
| TW (1) | TW201022238A (es) |
| WO (1) | WO2010055023A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110431A1 (es) | 2008-11-11 | 2011-07-13 | Boehringer Ingelheim Int | Etexilato de dabigatran o una sal del mismo |
| WO2011156587A2 (en) * | 2010-06-09 | 2011-12-15 | Daiichi Sankyo, Inc. | Methods and systems for anticoagulation risk-benefit evaluations |
| PL2550966T3 (pl) * | 2011-07-25 | 2017-03-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Estry kwasu amidooksymokarboksylowego dabigatranu jako proleki i ich zastosowanie jako lek |
| CN103127109B (zh) * | 2013-02-05 | 2014-08-13 | 南京华威医药科技开发有限公司 | 含达比加群酯或其盐和水合物的药用组合 |
| RU2595238C1 (ru) * | 2015-05-18 | 2016-08-20 | Галина Александровна Суханова | Способ лечения подострых венозных тромбозов различной локализации |
| RU2762945C1 (ru) * | 2021-03-02 | 2021-12-24 | Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии И Реабилитологии" (Фнкц Рр) | Способ антикоагулянтной терапии и профилактики тромботических осложнений у пациентов с тяжелым повреждением головного мозга в хроническом критическом состоянии |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006524203A (ja) * | 2003-04-24 | 2006-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用 |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| EP2043631A2 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New indications for direct thrombin inhibitors in the cardiovascular field |
-
2009
- 2009-11-10 EP EP09748791A patent/EP2358367A1/en not_active Withdrawn
- 2009-11-10 AR ARP090104348A patent/AR074108A1/es unknown
- 2009-11-10 NZ NZ592613A patent/NZ592613A/xx not_active IP Right Cessation
- 2009-11-10 AU AU2009315731A patent/AU2009315731A1/en not_active Abandoned
- 2009-11-10 KR KR1020117010629A patent/KR20110082563A/ko not_active Withdrawn
- 2009-11-10 TW TW098138139A patent/TW201022238A/zh unknown
- 2009-11-10 RU RU2011123367/15A patent/RU2530645C2/ru not_active IP Right Cessation
- 2009-11-10 US US13/128,463 patent/US20110251160A1/en not_active Abandoned
- 2009-11-10 CN CN2013101422468A patent/CN103340860A/zh active Pending
- 2009-11-10 WO PCT/EP2009/064875 patent/WO2010055023A1/en not_active Ceased
- 2009-11-10 MX MX2011004534A patent/MX2011004534A/es not_active Application Discontinuation
- 2009-11-10 CN CN2009801448120A patent/CN102209545A/zh active Pending
- 2009-11-10 BR BRPI0921353A patent/BRPI0921353A2/pt not_active IP Right Cessation
- 2009-11-10 CA CA2738885A patent/CA2738885A1/en not_active Abandoned
- 2009-11-10 JP JP2011535126A patent/JP2013510074A/ja active Pending
-
2011
- 2011-03-22 IL IL211854A patent/IL211854A0/en unknown
- 2011-04-12 CL CL2011000805A patent/CL2011000805A1/es unknown
-
2013
- 2013-09-06 US US14/019,906 patent/US20140045898A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103340860A (zh) | 2013-10-09 |
| CN102209545A (zh) | 2011-10-05 |
| EP2358367A1 (en) | 2011-08-24 |
| BRPI0921353A2 (pt) | 2015-12-29 |
| IL211854A0 (en) | 2011-06-30 |
| US20140045898A1 (en) | 2014-02-13 |
| TW201022238A (en) | 2010-06-16 |
| CA2738885A1 (en) | 2010-05-20 |
| JP2013510074A (ja) | 2013-03-21 |
| WO2010055023A1 (en) | 2010-05-20 |
| AU2009315731A1 (en) | 2010-05-20 |
| RU2011123367A (ru) | 2012-12-20 |
| US20110251160A1 (en) | 2011-10-13 |
| KR20110082563A (ko) | 2011-07-19 |
| MX2011004534A (es) | 2011-05-24 |
| RU2530645C2 (ru) | 2014-10-10 |
| CL2011000805A1 (es) | 2011-10-28 |
| NZ592613A (en) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074107A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
| CL2022002592A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
| ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
| AR074108A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| AR075423A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos | |
| JP2017505761A5 (es) | ||
| FI4243825T3 (fi) | Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
| AR081439A1 (es) | Composicion para el tratamiento de la hiperplasia prostatica benigna de prostata | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| AR119430A1 (es) | Métodos para tratar o prevenir la atrofia muscular espinal | |
| AR105752A1 (es) | Métodos para el tratamiento de enfermedades cardiovasculares | |
| Selvaraj et al. | Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| CO2020000529A2 (es) | Metodos para tratar hiperinsulinismo congenito | |
| AR132497A1 (es) | Combinación de obicetrapib amorfo e inhibidor de sglt2 | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| RU2004136583A (ru) | Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
| AR061635A1 (es) | Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos | |
| Elgariah et al. | Effect of terminal warm reperfusion (hot shot) and remote ischemic preconditioning, either separately or combined, on myocardial recovery in adult cardiac surgery | |
| Birkmayer | The importance of monoamine metabolism for the pathology of the extrapyramidal system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |